Compare RYTM & FNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | FNB |
|---|---|---|
| Founded | 2008 | 1864 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.8B |
| IPO Year | 2017 | 2002 |
| Metric | RYTM | FNB |
|---|---|---|
| Price | $104.05 | $17.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $140.29 | $20.33 |
| AVG Volume (30 Days) | 1.1M | ★ 5.8M |
| Earning Date | 11-03-2026 | 10-19-2026 |
| Dividend Yield | N/A | ★ 2.82% |
| EPS Growth | ★ 28.34 | 22.83 |
| EPS | N/A | ★ 1.23 |
| Revenue | N/A | N/A |
| Revenue This Year | $73.80 | $5.97 |
| Revenue Next Year | $73.86 | $6.59 |
| P/E Ratio | ★ N/A | $15.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.50 | $15.21 |
| 52 Week High | $122.20 | $19.59 |
| Indicator | RYTM | FNB |
|---|---|---|
| Relative Strength Index (RSI) | 70.69 | 60.53 |
| Support Level | $98.83 | $17.63 |
| Resistance Level | $117.84 | $18.89 |
| Average True Range (ATR) | 5.13 | 0.39 |
| MACD | 1.91 | 0.10 |
| Stochastic Oscillator | 94.41 | 76.81 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments, and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management, and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.